Trial Profile

Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prasugrel (Primary) ; Aspirin
Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery restenosis; Unstable angina pectoris
Focus Pharmacodynamics
Acronyms A-MATCH

Most Recent Events

05 Jan 2021 Primary endpoint has been met. (percentage of patients within the therapeutic window of platelet reactivity (85PRU208))
05 Jan 2021 Results published in the Thrombosis and Haemostasis
14 Sep 2015 Status changed from recruiting to completed, as reported at the 64th Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com